Abatacept biosimilar - Dr. Reddy's Laboratories
Alternative Names: DRL-ABLatest Information Update: 15 Jan 2024
At a glance
- Originator Dr Reddys Laboratories
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies; Urologics
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 03 Oct 2023 Phase-II clinical trials in Rheumatoid arthritis (In volunteers) in USA (Parenteral) (NCT06126042)